Selinexor, Pomalidomide, and Dexamethasone With or Without Carfilzomib for the Treatment of Patients With Relapsed Refractory Multiple Myeloma, The SCOPE Trial
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
Clinical Trials Related to Pomalidomide
Related studies linked through entity extraction aliases.
The Efficacy and Safety of Pomalidomide and Bendamustine With Dexamethasone in Relapsed or Refractory Multiple Myeloma
- Status
- UNKNOWN
- Phase
- PHASE1/PHASE2
A Study of Teclistamab With Other Anticancer Therapies in Participants With Multiple Myeloma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
A Study of Daratumumab With Pomalidomide, Dexamethasone, and All-Transretinoic Acid in Patients With Multiple Myeloma
- Status
- TERMINATED
- Phase
- PHASE2
CPD-DARA in Patients With Relapsed/Refractory Multiple Myeloma.
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
A Study of Selinexor, in Combination With Carfilzomib, Daratumumab or Pomalidomide in Patients With Multiple Myeloma
- Status
- SUSPENDED
- Phase
- PHASE2
Isatuximab in Combination With Novel Agents in RRMM - Master Protocol
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Phase II Study of Immunomaintenance Using POmalidomide With Elotuzumab afteR Second Autologous Transplant
- Status
- WITHDRAWN
- Phase
- PHASE2
Pomalidomide Treatment in Patients With Kaposi Sarcoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Leflunomide, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma
- Status
- RECRUITING
- Phase
- PHASE2
Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
A Prospective, Non-interventional, Multinational, Observational Study With Isatuximab in Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- N/A
A Study to Evaluate the Safety, Tolerability and Efficacy of Intravenous TAK-573 as Part of Combination Therapy in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
- Status
- WITHDRAWN
- Phase
- PHASE1
INCB053914 and Pomalidomide With Dexamethasone for Relapsed and/or Refractory Multiple Myeloma
- Status
- WITHDRAWN
- Phase
- PHASE1
A Phase II Study of Daratumumab, Clarithromycin, Pomalidomide And Dexamethasone (D-ClaPd) In Multiple Myeloma Patients Previously Exposed to Daratumumab
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Multicenter Open Label Phase 2 Study of Isatuximab Plus Pomalidomide and Dexamethasone With Carfilzomib in Relapsed or Refractory Multiple Myeloma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Relapsed/Refractory Light Chain Amyloidosis Patients Previously Exposed to Daratumumab
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Study of Early Relapsed, Lenalidomide-refractory Subjects Eligible for Carfilzomib Triplet
- Status
- COMPLETED
- Phase
- PHASE2
A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM
- Status
- RECRUITING
- Phase
- PHASE2